JPMorgan Chase & Co. (JPM-PK)
| Previous Close | 20.28 |
| Open | 20.30 |
| Bid | 17.99 x 800 |
| Ask | 23.32 x 1000 |
| Day's Range | 20.12 - 20.35 |
| 52 Week Range | 18.32 - 21.69 |
| Volume | |
| Avg. Volume | 130,595 |
| Market Cap | N/A |
| Beta (5Y Monthly) | 1.12 |
| PE Ratio (TTM) | 1.50 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.14 (5.63%) |
| Ex-Dividend Date | May 01, 2024 |
| 1y Target Est | N/A |
- Business Wire
JPMorgan Chase Declares Common Stock Dividend
NEW YORK, May 20, 2024--JPMorgan Chase & Co. (NYSE: JPM) ("JPMorgan Chase" or the "Firm") declared a quarterly dividend on the outstanding shares of the common stock of JPMorgan Chase. Information can be found on the Firm’s Investor Relations website at https://www.jpmorganchase.com/ir/news.
- PR Newswire
J.P. Morgan Asset Management Launches Active Developing Markets Equity ETF: JADE
J.P. Morgan Asset Management today announced the launch of a new actively managed ETF, JPMorgan Active Developing Markets Equity ETF (JADE), on the NYSE Arca. The fund will invest in emerging markets equity securities.
- PR Newswire
J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Announce Winner of Inaugural 2024 Life Sciences Innovation Summit
J.P. Morgan Life Sciences Private Capital, Blue Horizon Advisors and United Al Saqer Group today announced Rayees Rahman of Harmonic Discovery as the winner of the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. Harmonic Discovery is a precision pharmacology company applying its generative chemistry platform to advance next-generation kinase inhibitors.
